BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 23494713)

  • 1. Mature T/NK-cell lymphoproliferative disease and Epstein-Barr virus infection are more frequent in patients with rheumatoid arthritis treated with methotrexate.
    Kondo S; Tanimoto K; Yamada K; Yoshimoto G; Suematsu E; Fujisaki T; Oshiro Y; Tamura K; Takeshita M; Okamura S
    Virchows Arch; 2013 Apr; 462(4):399-407. PubMed ID: 23494713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication.
    Hoshida Y; Xu JX; Fujita S; Nakamichi I; Ikeda J; Tomita Y; Nakatsuka S; Tamaru J; Iizuka A; Takeuchi T; Aozasa K
    J Rheumatol; 2007 Feb; 34(2):322-31. PubMed ID: 17117491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathological findings, prognosis, and Epstein-Barr virus infection in rheumatoid arthritis patients with other iatrogenic immunodeficiency-associated T- and NK-cell lymphoproliferative disorders.
    Kimura S; Oshiro Y; Iwasaki H; Kadowaki M; Ogata M; Daa T; Sakata T; Kawauchi S; Wang Z; Takamatsu Y; Takeshita M
    BMC Cancer; 2022 Dec; 22(1):1342. PubMed ID: 36544095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methotrexate-associated lymphoproliferative disorder presenting as extranodal NK/T-cell lymphoma arising in the lungs.
    Tajima S; Takanashi Y; Koda K; Fukayama M
    Pathol Int; 2015 Dec; 65(12):661-5. PubMed ID: 26459854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epstein-Barr virus infection and gene promoter hypermethylation in rheumatoid arthritis patients with methotrexate-associated B cell lymphoproliferative disorders.
    Ejima-Yamada K; Oshiro Y; Okamura S; Fujisaki T; Mihashi Y; Tamura K; Fukushige T; Kojima M; Shibuya K; Takeshita M
    Virchows Arch; 2017 Feb; 470(2):205-215. PubMed ID: 27864689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epstein-Barr virus-related lymphoma in rheumatoid arthritis: implications for long-term usage of immunosuppressive drugs and review of the literature.
    He J; Williamson L; Cai K; Wong P; Sturgess A; Taper J; Manolios N
    Intern Med J; 2022 Oct; 52(10):1717-1723. PubMed ID: 34028145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methotrexate/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression.
    Ichikawa A; Arakawa F; Kiyasu J; Sato K; Miyoshi H; Niino D; Kimura Y; Takeuchi M; Yoshida M; Ishibashi Y; Nakashima S; Sugita Y; Miura O; Ohshima K
    Eur J Haematol; 2013 Jul; 91(1):20-8. PubMed ID: 23560463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methotrexate-related Epstein-Barr Virus (EBV)-associated lymphoproliferative disorder--so-called "Hodgkin-like lesion"--of the oral cavity in a patient with rheumatoid arthritis.
    Kikuchi K; Miyazaki Y; Tanaka A; Shigematu H; Kojima M; Sakashita H; Kusama K
    Head Neck Pathol; 2010 Dec; 4(4):305-11. PubMed ID: 20676828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymphoproliferative disorders in patients with rheumatoid arthritis in the era of widespread use of methotrexate: A review of the literature and current perspective.
    Harigai M
    Mod Rheumatol; 2018 Jan; 28(1):1-8. PubMed ID: 28758827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors of methotrexate-associated lymphoproliferative disorders associated with rheumatoid arthritis and plausible application of biological agents.
    Katsuyama T; Sada KE; Yan M; Zeggar S; Hiramatsu S; Miyawaki Y; Ohashi K; Morishita M; Watanabe H; Katsuyama E; Takano-Narazaki M; Toyota-Tatebe N; Sunahori-Watanabe K; Kawabata T; Miyake K; Kiguchi T; Wada J
    Mod Rheumatol; 2017 Sep; 27(5):773-777. PubMed ID: 27846761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spontaneous regression of breast lymphoproliferative disorders after withdrawal of methotrexate in rheumatoid arthritis patients with Epstein-Barr virus infection: a case report and review of the literature.
    Ogawa A; Nakagawa T; Kumaki Y; Hosoya T; Oda G; Mori M; Fujioka T; Kubota K; Onishi I; Uetake H
    J Med Case Rep; 2022 Feb; 16(1):49. PubMed ID: 35125110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A clinical, pathological, and genetic characterization of methotrexate-associated lymphoproliferative disorders.
    Yamakawa N; Fujimoto M; Kawabata D; Terao C; Nishikori M; Nakashima R; Imura Y; Yukawa N; Yoshifuji H; Ohmura K; Fujii T; Kitano T; Kondo T; Yurugi K; Miura Y; Maekawa T; Saji H; Takaori-Kondo A; Matsuda F; Haga H; Mimori T
    J Rheumatol; 2014 Feb; 41(2):293-9. PubMed ID: 24334644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methotrexate-related Epstein-Barr virus-associated lymphoproliferative disorder occurring in the gingiva of a patient with rheumatoid arthritis.
    Ishida M; Hodohara K; Yoshii M; Okuno H; Horinouchi A; Nakanishi R; Harada A; Iwai M; Yoshida K; Kagotani A; Yoshida T; Okabe H
    Int J Clin Exp Pathol; 2013; 6(10):2237-41. PubMed ID: 24133604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD8(+) T-cell lymphoproliferative disorder associated with Epstein-Barr virus in a patient with rheumatoid arthritis during methotrexate therapy.
    Hatachi S; Kunitomi A; Aozasa K; Yagita M
    Mod Rheumatol; 2010 Oct; 20(5):500-5. PubMed ID: 20437072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methotrexate-associated Lymphoproliferative Disorders in Patients With Rheumatoid Arthritis: Clinicopathologic Features and Prognostic Factors.
    Kurita D; Miyoshi H; Ichikawa A; Kato K; Imaizumi Y; Seki R; Sato K; Sasaki Y; Kawamoto K; Shimono J; Yamada K; Muto R; Kizaki M; Nagafuji K; Tamaru JI; Tokuhira M; Ohshima K
    Am J Surg Pathol; 2019 Jul; 43(7):869-884. PubMed ID: 31116708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases.
    Salloum E; Cooper DL; Howe G; Lacy J; Tallini G; Crouch J; Schultz M; Murren J
    J Clin Oncol; 1996 Jun; 14(6):1943-9. PubMed ID: 8656264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathological characteristics and rituximab addition to cytotoxic therapies in patients with rheumatoid arthritis and methotrexate-associated large B lymphoproliferative disorders.
    Yamada K; Oshiro Y; Okamura S; Fujisaki T; Kondo S; Nakayama Y; Suematsu E; Tamura K; Takeshita M
    Histopathology; 2015 Jul; 67(1):70-80. PubMed ID: 25429725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of methotrexate-associated lymphoproliferative disorders in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs.
    Harada T; Iwasaki H; Muta T; Urata S; Sakamoto A; Kohno K; Takase K; Miyamura T; Sawabe T; Asaoku H; Oryoji K; Fujisaki T; Mori Y; Yoshimoto G; Ayano M; Mitoma H; Miyamoto T; Niiro H; Yamamoto H; Oshiro Y; Miyoshi H; Ohshima K; Takeshita M; Akashi K; Kato K
    Br J Haematol; 2021 Jul; 194(1):101-110. PubMed ID: 33822354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymorphic lymphoproliferative disorder arising in a rheumatoid arthritis patient, presenting as fibrin-associated large B-cell lymphoma-like lesions in aortic and mitral valves.
    Tsujii H; Nakayama R; Funakoshi S; Tsuji S; Haga H; Ono K
    Pathol Int; 2024 May; 74(5):285-291. PubMed ID: 38563592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Remission of lymphoma after withdrawal of methotrexate in rheumatoid arthritis: relationship with type of latent Epstein-Barr virus infection.
    Miyazaki T; Fujimaki K; Shirasugi Y; Yoshiba F; Ohsaka M; Miyazaki K; Yamazaki E; Sakai R; Tamaru J; Kishi K; Kanamori H; Higashihara M; Hotta T; Ishigatsubo Y
    Am J Hematol; 2007 Dec; 82(12):1106-9. PubMed ID: 17654684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.